Pharmaceuticals Durect’s Lalcostosterol Receives FDA Breakthrough Treatment Designation for Severe Alcohol-Related Hepatitis Last updated: May 22, 2024 3:30 pm By bexib 0 Min Read Share SHARE Going forward, Durect plans to incorporate feedback from the FDA into the design of its Phase 3 trial. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article Would you like to start a food truck business? What you need to know about costs (2024) Next Article Current Markets, Land Prices, and the Importance of Trade Access, March 16, 2024 – RealAgriculture Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Upskilling: An interview with Steph Piper Manufacturing Young Kiwis toast change: hazardous drinking falls by 13% in five years Hospitality & Tourism Clearview FCU saves 6,000 labor hours through RPA Banking Inside Varo Bank’s GEN AI Copilot build Banking